R&D at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s R&D?
- Vaxcyte, Inc. (PCVX) reported R&D of $312.78M in Q1 2026.
- How has Vaxcyte, Inc.'s R&D changed year-over-year?
- Vaxcyte, Inc.'s R&D increased by 111.1% year-over-year, from $148.13M to $312.78M.
- What is the long-term trend for Vaxcyte, Inc.'s R&D?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s R&D has grown at a 78.4% compound annual growth rate (CAGR), from $78.41M to $794.31M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.